ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237)
Previous Study | Return to List | Next Study

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02530619
Recruitment Status : Active, not recruiting
First Posted : August 21, 2015
Last Update Posted : February 16, 2018
Sponsor:
Collaborators:
The Leukemia and Lymphoma Society
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Brady Stein, Northwestern University

August 18, 2015
August 21, 2015
February 16, 2018
October 2015
July 2019   (Final data collection date for primary outcome measure)
Incidence of adverse events [ Time Frame: Up to 6 months after the last dose of treatment ]
The number, frequency, and severity of adverse events will be recorded every cycle for each population. All patients who receive at least 1 dose of alisertib will be considered evaluable for this endpoint.
Same as current
Complete list of historical versions of study NCT02530619 on ClinicalTrials.gov Archive Site
Response to treatment [ Time Frame: Baseline to up to 6 months after the last dose of treatment ]
Serial blood and/or bone marrow samples will be collected at specific timepoints for each disease to determine response to alisertib treatment.
Same as current
  • Changes in biomarker expression levels [ Time Frame: Baseline to up to 6 months after the last dose of treatment ]
    To evaluate the relationship between biomarker expression levels and response. Biomarkers will include a) genes encoding key enzymes in Aurora kinase signaling, b) markers of cellular aneuploidy and apoptosis, and c) markers of megakaryocytic differentiation.
  • Changes in MF symptoms assessed by the MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment form) score (MF patients) [ Time Frame: Once per cycle (1 cycle=21 days) ]
    To evaluate improvement in MF symptoms in the MF arm, changes in symptom scores over time will be calculated.
  • Changes in pharmacodynamic effects of alisertib [ Time Frame: Baseline to up to 6 months after the last dose of treatment ]
    Serial blood and/or bone marrow samples will be collected at specific timepoints. Flow cytometry, colony forming assays, AURKA autophosphorylation assays, and in vitro cultures of patient specimens to assess the effect of MLN8237 on megakaryocytes and other hematopoietic cells will be measured.
  • Changes in splenomegaly by palpation (MF patients) [ Time Frame: Baseline to up to 6 months after the last dose of treatment ]
    To evaluate reduction in splenomegaly by palpation in the MF arm. Patients will be examined for splenomegaly by palpation once per cycle and change from baseline will be calculated over time.
  • Change in bone marrow fibrosis (MF patients) [ Time Frame: Screening and up to 54 weeks ]
    Assess change in bone marrow fibrosis in patients in the MF arm. Bone marrow will be assessed at screening and after cycle 6 in this population.
Same as current
 
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase A, in Adult Patients With Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)
The purpose of this study is to evaluate the safety of alisertib and its effect, bad and/or good, on acute megakaryoblastic leukemia (AMKL) or myelofibrosis (MF). The study drug, alisertib, is an investigational drug. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Alisertib has shown evidence in the lab that it may have an effect on a type of cell that produces platelets. This cell is called a megakaryocyte and it is known to be defective (doesn't work well) in both AMKL and MF.

PRIMARY OBJECTIVES:

I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF).

SECONDARY OBJECTIVES:

I. Determine preliminary efficacy of alisertib in both populations.

TERCIARY OBJECTIVES:

I. Describe pharmacodynamics (PD) effects of alisertib in peripheral blood and/or bone marrow samples.

II. Evaluate the relationship between biomarker expression levels and response to alisertib.

III. Evaluate reduction in splenomegaly by palpation (MF arm only). IV. Evaluate improvement in MF symptoms (MF arm only), as assessed by the Myeloproliferative Neoplasm Symptom Assessment form (MPN-SAF).

V. Assess change in bone marrow fibrosis in patients in the MF arm.

OUTLINE:

Patients receive alisertib orally (PO) twice daily (BID) on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at approximately 30 days and 6 months.

Interventional
Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Acute Megakaryoblastic Leukemia
  • Myelofibrosis
  • Primary Myelofibrosis
  • Drug: Alisertib
    Given PO
    Other Names:
    • Aurora A Kinase Inhibitor MLN8237
    • MLN-8237
    • MLN8237
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Other: Pharmacological Study
    Correlative studies
Experimental: Treatment (alisertib)
Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: Alisertib
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
26
24
March 2020
July 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • AMKL PATIENTS: Patients must have a confirmed diagnosis of relapsed/refractory acute megakaryoblastic leukemia (AMKL), as defined by World Health Organization (WHO) criteria
  • AMKL PATIENTS: Patients must have an Eastern Cooperative Oncology Group (ECOG) status 0-2
  • AMKL PATIENTS: Total bilirubin =< 1.5 x upper limit of normal (ULN)
  • AMKL PATIENTS: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
  • AMKL PATIENTS: Creatinine < 1.5 x ULN or calculated creatinine clearance > 30 ml/min
  • AMKL PATIENTS: Prothrombin time (PT) and partial thromboplastin time (PTT) =< 1.5 x ULN
  • AMKL PATIENTS: Absolute neutrophil count (ANC) >= 1500/mm^3
  • AMKL PATIENTS: Platelets >= 100,000/mm^3
  • AMKL PATIENTS: Hemoglobin > 9 g/dL
  • AMKL PATIENTS: Patients must have estimated life expectancy of 6 months or greater
  • AMKL PATIENTS: Female patients of child-bearing potential (FOCBP) must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test within 7 days prior to registration; NOTE: a FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy
    • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
  • AMKL PATIENTS: Female patients must meet at least one of the following conditions:

    • Must be post-menopausal for at least 1 year prior to registration (not of childbearing potential)
    • Must be surgically sterilized
    • Willing to use an acceptable method of birth control (i.e. hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study
  • AMKL PATIENTS: Male patients, even if surgically sterilized (status post-vasectomy) agrees to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of alisertib
  • AMKL PATIENTS: Patients must be able to understand and willing to sign a written informed consent
  • MF PATIENTS: Patients must have a confirmed diagnosis of myelofibrosis (MF), as defined by WHO criteria
  • MF PATIENTS: Patients must be intermediate I risk or beyond and meet the following:

    • In need of treatment
    • Intolerant or refractory to ruxolitinib (or other investigational Janus kinase [JAK]-inhibitors) OR unlikely to benefit from ruxolitinib
    • Ineligible for stem cell transplantation
  • MF PATIENTS: Patients must have an ECOG status 0-2
  • MF PATIENTS: Direct bilirubin < 1.5 x ULN
  • MF PATIENTS: ALT/AST =< 2.5 x ULN
  • MF PATIENTS: Creatinine < 1.5 x ULN or calculated creatinine clearance > 30 ml/min
  • MF PATIENTS: PT and PTT =< 1.5 x ULN
  • MF PATIENTS: ANC >= 1500/mm^3
  • MF PATIENTS: Platelets >= 100,000/mm^3
  • MF PATIENTS: Patients must have estimated life expectancy of 6 months or greater
  • MF PATIENTS: Female patients of child-bearing potential (FOCBP) must have a negative serum beta-HCG pregnancy test within 7 days prior to registration
  • MF PATIENTS: Female patients must meet at least one of the following conditions:

    • Must be post-menopausal for at least 1 year prior to registration (not of childbearing potential)
    • Must be surgically sterilized
    • Willing to use an acceptable method of birth control (i.e. hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study
  • MF PATIENTS: Male patients, even if surgically sterilized (i.e. status post-vasectomy) agrees to use an acceptable method for contraception during the entire study treatment period through 4 months after the last dose of alisertib
  • MF PATIENTS: Patients must be able to understand and willing to sign a written informed consent

Exclusion Criteria:

  • Patients who have received treatment with clinically significant enzyme inducers (such as enzyme inducing antiepileptic drugs phenytoin, carbamazepine, or phenobarbital, or rifampin, rifabutin, rafapentine, or St. John's wort) within 14 days prior to registration are not eligible
  • Patients who have received any investigational products, antineoplastic therapies, or radiotherapy within 14 days prior to registration are not eligible; NOTE: patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea through cycle 1 of protocol treatment
  • Patients who have received prior administration of an Aurora A kinase targeted agent (including alisertib) are not eligible
  • Patients who have received corticosteroids within 7 days prior registration are not eligible, UNLESS the patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 1 month prior; NOTE: low dose steroid use for control of nausea and vomiting will be allowed; topical steroid use and inhaled steroids are also permitted
  • Patients who are candidates (eligible and willing) for standard and/or potentially curative treatments are not eligible
  • Patients who have had received radiation therapy to more than 25% of the bone marrow are not eligible (whole pelvic radiation is considered to be over 25%)
  • Patients who have had major surgery within one month (28 days) prior to registration are not eligible
  • Patients who have had prior allogenic bone marrow or organ transplantation are not eligible
  • Patients who have had grade 2 or higher diarrhea, despite optimal antidiarrheal supportive care, within 7 days prior to registration are not eligible
  • Patients who have had grade 2 or higher peripheral neuropathy within 14 days prior to registration are not eligible
  • Patients who have had a myocardial infarction within 6 months (24 weeks) prior to registration are not eligible
  • Patients who have class III or IV heart failure (as defined by the New York Heart Association), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities are not eligible
  • Patients who have known gastrointestinal (GI) disease or GI procedures which could interfere with the oral absorption or tolerance of alisertib are not eligible; examples include (but are not limited to) partial gastrectomy, history of small intestine surgery, and celiac disease
  • Patients who have a known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness (such as severe chronic obstructive pulmonary disease or requirement for supplemental oxygen) are not eligible
  • Patients who have a requirement for constant administration of proton pump inhibitor, histamine-2 (H2) antagonist, or pancreatic enzymes are not eligible; intermittent usage of antacids or H2 antagonists are allowed
  • Patients who have a systemic infection requiring intravenous (IV) antibiotic therapy within 14 days prior to registration (or other severe infection) are not eligible
  • Patients who are known human immunodeficiency virus (HIV) positive are not eligible
  • Patients who are known hepatitis B surface antigen positive are not eligible
  • Patients who have known or suspected active hepatitis C infections are not eligible; NOTE: patients who are hepatitis C surface antigen positive are eligible
  • Female patients who are pregnant or breast feeding are not eligible
  • Patients who have a severe acute or chronic medical or psychiatric condition, including uncontrolled diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement for pancreatic enzymes, any condition that would modify small bowel absorption of oral medications, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study are not eligible
  • Patients who have symptomatic central nervous system (CNS) involvement are not eligible
  • Patients who have been diagnosed or treated for another malignancy within 3 years prior to registration are not eligible aside from these exceptions: completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
  • Patients who are unable to swallow oral medication or are unwilling to comply with the administration requirements are not eligible
  • Patients who require administration of myeloid growth factors or platelet transfusions within 14 days prior to registration are not eligible
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02530619
NU 15H10
NCI-2015-01219 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
STU00200682
NU 15H10 ( Other Identifier: Northwestern University )
P30CA060553 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Brady Stein, Northwestern University
Northwestern University
  • The Leukemia and Lymphoma Society
  • Millennium Pharmaceuticals, Inc.
  • National Cancer Institute (NCI)
Principal Investigator: Brady Stein, MD Northwestern University
Northwestern University
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP